We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most website use to personalize your web experience. By continuing to browse the site you are giving your consent for us to set cookies. If you wish to restrict or block cookies which are set on your device then you can do this through your browser settings.
Find out more about cookies here: Privacy Policy
OkBy following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.
ContinueNotice
Welcome to Medically. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United States of America (US), the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche does not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website. Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice and Roche accepts no responsibility for access to or use of the same. To access the full range of product and disease information, congress and educational materials available on this website, you will be required to register and log-in. By clicking “I confirm” below you are confirming that you are a healthcare professional outside the US, the UK, and Australia that you have read and understood this message and that you are requesting access to Medically.
This website is intended only for healthcare professionals outside the US, UK and Australia.
Huntington’s disease is a genetic, neurodegenerative and ultimately fatal disease with devastating impact on individuals and entire families. Despite knowing the exact cause of Huntington’s disease since 1993, there still remains much unknown about this complex brain disease. In this animation, Lauren Byrne, a Research Fellow at the UCL Huntington's Disease Centre shares her personal experience with Huntington's. She takes us inside the brain to explore the mechanism of this disease leading to the cognitive, behavioural and motor symptoms in Huntington's.
This video illustrates the latest understanding around the mechanism of disease and the main pathways being targeted to develop new treatment for Alzheimer's disease
This video describes the immense challenge the societies have to face with Alzheimer's disease. This challenge is growing and disease becoming epidemic in the future, and remains the only major disease without any available disease-modifying therapy.
The benefits of medicinal cannabinoids for the treatment of spasticity, pain and bladder dysfunction in patients with multiple sclerosis (MS) may be limited, suggests a systematic review and meta-analysis.
The insulin-like growth factor-1 (IGF-1) pathway may be a suitable treatment target for patients with spinal and bulbar muscular atrophy, suggest preliminary findings.
Study findings show an increased risk of dementia in older people with atrial fibrillation (AF) and support the use of anticoagulants to reduce the likelihood.
The global burden of Parkinson’s disease has more than doubled over the past 26 years, show findings from the Global Burden of Disease Study 2016.
A retrospective analysis of a cohort of children and adolescents with Huntington’s disease points to the presence of two juvenile forms that have markedly different clinical features and prognosis.
The positron emission tomography (PET) tracer [18F]flortaucipir could be a useful test for distinguishing Alzheimer’s disease (AD) from other neurodegenerative disorders, say researchers.
Adolescents with multiple sclerosis may experience fewer relapses if they take fingolimod versus interferon beta-1a, suggest findings from the phase III PARADIGMS trial.
Plasma neurofilament light protein (NfL) concentrations and cerebrospinal fluid (CSF) biomarkers are effective for diagnosing Alzheimer’s disease (AD) in patients with Down syndrome, say researchers.
Ibudilast may slow brain atrophy in patients with progressive multiple sclerosis, show findings from a phase II study.
Researchers have discovered a new subtype of multiple sclerosis (MS) that features neuronal loss but not demyelination of the brain’s white matter.
Findings from a large registry-based study support an increased risk of suicide following traumatic brain injury (TBI).
Superimposed relapses are associated with a lower risk of confirmed disability progression among individuals with progressive-onset multiple sclerosis (MS), suggest the results of an observational cohort study published in JAMA Neurology
Subcutaneous apomorphine infusion meaningfully reduces the time in which a patient’s medication is not working optimally and parkinsonian symptoms return, reports the placebo-controlled, multicentre TOLEDO trial.
Reduced levels of γ-aminobutyric acid (GABA) in the primary visual cortex are linked to visual hallucinations in patients with Parkinson’s disease (PD), study findings indicate.
This slide provides an overview of the key unmet needs in Alzheimer's disease
